Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 9 , Pages 1138-1141 , September 2006

Pharmacological Management of a Youth With ADHD, Marijuana Use, and Mood Symptoms

,Accepted 16 April 2006.

REFERENCES 

  1. AACAP  . Practice parameter for the assessment and treatment of children and adolescent with substance use disorders . J Am Acad Child Adolesc Psychiatry . 2004;44:609–621
  2. Biederman J , Faraone S . Attention-deficit hyperactivity disorder . Lancet . 2005;366:237–248
  3. Biederman J , Wilens T , Mick E , et al.   Is ADHD a risk for psychoactive substance use disorder? Findings from a four year follow-up study . J Am Acad Child Adolesc Psychiatry . 1997;36:21–29
  4. Daviss WB , Bentivoglio P , Racusin R , Brown KM , Bostic JQ , Wiley L . Bupropion SR in adolescents with combined attention-deficit/hyperactivity disorder and depression . J Am Acad Child Adolesc Psychiatry . 2001;40:307–314
  5. Dennis M , Godley SH , Diamond G , et al.   The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials . J Subst Abuse Treat . 2004;27:197–213
  6. Huestis MA , Cone EJ . Differentiating new marijuana use from residual drug excretion in occasional marijuana users . J Anal Toxicol . 1998;22:445–454
  7. Jasinski DR . An evaluation of the abuse potential of modafinil using methylphenidate as a reference . J Psychopharmacol . 2000;14:53–60
  8. Le Foll B , Goldberg SR . Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence . J Pharmacol Exp Ther . 2005;312:875–883
  9. Libby AM , Riggs PD . Integrated substance use and mental health treatment for adolescents: aligning organizational and financial incentives . J Child Adolesc Psychopharmacol . 2005;15:826–834
  10. McCabe SE , Knight JR , Teter CJ , Wechsler H . Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey . Addiction . 2005;99:96–106
  11. Parasrampuria D, Schoedel K, Schuller R et al. (2005), Abuse potential of OROS methylphenidate versus immediate-release methylphenidate and placebo. Paper presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, October 18-23
  12. Riggs P , Leon S , Mikulich S , Pottle L . An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder . J Am Acad Child Adolesc Psychiatry . 1998;37:1271–1278
  13. Riggs PD . Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder . J Am Acad Child Adolesc Psychiatry . 1998;37:331–332
  14. Solhkhah R , Wilens TE , Daly J , Prince JB , Patten SL , Biederman J . Bupropion SR for the treatment of substance- abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders . J Child Adolesc Psychopharmacol . 2005;15:777–786
  15. Spencer T , Biederman J , Ciccone P , et al.   PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate . Am J Psychiatry . 2006;163:387–395
  16. Wilens T , Gignac M , Swezey A , Monuteaux M , Biederman J . Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications . J Am Acad Child Adolesc Psychiatry . 2006;45:408–414
  17. Wilens T , Monuteaux M , Snyder L , Moore BA . The clinical dilemma of using medications in substance abusing adolescents and adults with ADHD: what does the literature tell us? . J Child Adolesc Psychopharmacol . 2005;15:787–798
  18. Wilson JJ , Levin FR . Attention-deficit/hyperactivity disorder and early-onset substance use disorders . J Child Adolesc Psychopharmacol . 2005;15:751–763

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.

PII: S0890-8567(09)61789-5

doi: 10.1097/01.chi.0000228126.34085.79

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 9 , Pages 1138-1141 , September 2006

Article Tools